Certified Advisory Corp’s Teva Pharmaceuticals TEVA Stock Holding History

Certified Advisory Corp’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-711	Closed	-$8K	–	676
2021 Q1	$8K	Buy	+711	New	+$8.15K	﹤0.01%	629
2020 Q2	$9K	Hold	711	–	–	﹤0.01%	573
2020 Q1	$6K	Hold	711	–	–	﹤0.01%	605
2019 Q4	$7K	Sell	711 -350	-33%	-$3.13K	﹤0.01%	632
2019 Q3	$7K	Hold	1,061	–	–	﹤0.01%	647
2019 Q2	$10K	Hold	1,061	–	–	﹤0.01%	587
2019 Q1	$17K	Hold	1,061	–	–	0.01%	479
2018 Q4	$16K	Hold	1,061	–	–	0.01%	469
2018 Q3	$23K	Hold	1,061	–	–	0.01%	424
2018 Q2	$26K	Hold	1,061	–	–	0.01%	379
2018 Q1	$18K	Sell	1,061 -115	-10%	-$2.25K	0.01%	430
2017 Q4	$22K	Buy	+1,176	New	+$17.7K	0.02%	354

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Certified Advisory Corp's TEVA Position: Q2 2021 in Review

Certified Advisory Corp sold out of Teva Pharmaceuticals (TEVA) in Q2 2021, closing a stake of 711 shares — an estimated $8K sold.

Certified Advisory Corp first reported a position in TEVA in Q4 2017 and held it in 12 quarters. The position peaked at $26K in Q2 2018. 440 funds tracked by Wall St. Rank hold TEVA as of Q2 2021.

Certified Advisory Corp reported no remaining Teva Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Certified Advisory Corp sold 711 Teva Pharmaceuticals shares in Q2 2021, an estimated $8K.
Certified Advisory Corp first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 12 quarters.
Certified Advisory Corp's Teva Pharmaceuticals position peaked at $26K in Q2 2018.
440 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2021.

Based on Certified Advisory Corp's 13F filing for Q2 2021, filed 16 Aug 2021.